Citigroup Reiterates Outperform as Intellia Files BLA and Seeks $150M
Citigroup reiterated an Outperform rating for Intellia Therapeutics after it initiated a rolling BLA submission for lonvo-z following positive Phase 3 results preventing hereditary angioedema attacks. The company also unveiled a $150 million public offering as its stock dipped by 4.3% to support the FDA approval process.
1. BLA Submission Initiated
Intellia Therapeutics has commenced a rolling Biologics License Application with the FDA for lonvo-z, its one-time CRISPR-based therapy targeting hereditary angioedema. This structured submission allows the company to provide data modules as they become available, expediting the review timeline.
2. Phase 3 Trial Success
The Phase 3 trial demonstrated that a single dose of lonvo-z effectively prevented HAE attacks, meeting primary and key secondary endpoints. These robust efficacy results underpin the company’s confidence in pursuing regulatory approval.
3. Analyst Rating and Market Reaction
Citigroup reaffirmed an Outperform rating on Intellia following the BLA filing, reflecting optimism on the therapy’s market potential. Despite this endorsement, the stock declined 4.3% amid the equity raise announcement.
4. $150 Million Public Offering
To bolster its balance sheet through the FDA review, Intellia announced a $150 million public offering of common shares. Proceeds are earmarked for clinical development and regulatory activities surrounding lonvo-z.